Perimeter Medical Imaging AI Inc. secured FDA premarket approval for Claire, its AI-powered imaging device which detects difficult-to-see cancer during breast-conserving surgery. Claire combines AI with wide-field optical coherence tomography to provide surgeons with high-resolution, real-time views of excised tumor margins, to reduce the need for re-operations.

Japan has approved the world’s first therapies derived from induced pluripotent stem cells (iPSCs), marking a major milestone for regenerative medicine and, potentially, a turning point in treating Parkinson’s disease.

The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security.

One year on from establishing the baseline on female representation in the U.K. biotech industry, the latest survey shows the “dial is stuck.” Since the first report, representation at the CEO level has crept from 18.3% to 18.7%. That is “a marginal gain that signals a plateau at a time when we need a breakthrough,” said Jane Wall, managing director of the U.K. Bioindustry Association, which compiled the statistics.

Biopharma financings totaled $16.78 billion in the first two months of 2026, about an 81% year-over-year rise from $9.28 billion in January to February 2025. While still below the outsized $33.29 billion recorded in the same period of 2024, and $24.37 billion in 2021, the early 2026 total significantly outpaces the more subdued levels seen in 2022 ($7.48 billion) and 2023 ($7.66 billion).

Pricing shares at $20 each, below the intended price range, insulin delivery company Minimed Group Inc. debuted with an IPO on Nasdaq March 6, raising $560 million. The company offered a total of 28 million shares, which would have brought the Northridge, Calif.-based company $742 million in gross proceeds if the IPO had priced at the midpoint of the $25-to-$28 price range disclosed in February.